Generation Bio
Generation Bio is dedicated to transforming the treatment of T cell–driven autoimmune diseases through innovative siRNA therapeutics. Their proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective delivery of siRNA to T cells, allowing for precise modulation of immune responses while sparing the broader immune system. With a focus on unlocking undruggable targets and achieving genetic precision, Generation Bio aims to develop more potent, better-tolerated treatments. Their mission is driven by a team of experienced scientists and industry leaders committed to changing what’s possible for patients with autoimmune diseases.
Industries
Nr. of Employees
medium (51-250)
Generation Bio
Patents
Products
Cell-targeted lipid nanoparticle siRNA delivery platform
A modular, ligand-directed lipid nanoparticle platform engineered to deliver siRNA selectively to T cells, designed to modulate T cell function for development of therapeutics for T cell–driven autoimmune diseases.
Cell-targeted lipid nanoparticle siRNA delivery platform
A modular, ligand-directed lipid nanoparticle platform engineered to deliver siRNA selectively to T cells, designed to modulate T cell function for development of therapeutics for T cell–driven autoimmune diseases.
Expertise Areas
- RNA therapeutics (siRNA)
- Targeted nanoparticle delivery
- Lipid formulation chemistry
- Preclinical in vivo delivery and testing
Key Technologies
- siRNA therapeutics
- Lipid nanoparticle (LNP) delivery
- Ligand-directed cell targeting
- Ionizable lipid design
News & Updates
Research on ctLNPs for targeted delivery to T cells, enhancing therapeutic potential.
Study on the development of ctLNPs for T cell delivery.
Advancement in ctLNP technology for targeting various cell types.
Further development of ctLNPs for targeted genetic therapies.
Optimization of ctLNP stability and composition.
Research on in vivo delivery of T cells using ctLNP.
Research on ctLNPs for targeted delivery to T cells, enhancing therapeutic potential.
Study on the development of ctLNPs for T cell delivery.
Advancement in ctLNP technology for targeting various cell types.
Further development of ctLNPs for targeted genetic therapies.
Optimization of ctLNP stability and composition.
Research on in vivo delivery of T cells using ctLNP.